Get the Stockscreener App
9.176
3.16%
-0.314
Amicus Therapeutics Inc stock is traded at $9.176, with a volume of 952.84K.
It is down -3.16% in the last 24 hours and down -4.67% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$9.49
Open:
$9.47
24h Volume:
952.84K
Relative Volume:
0.42
Market Cap:
$2.85B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-26.99
EPS:
-0.34
Net Cash Flow:
$-31.51M
1W Performance:
-1.61%
1M Performance:
-4.67%
6M Performance:
-20.98%
1Y Performance:
-30.85%
1-Day Range:
$9.155
$9.47
1-Week Range:
$8.92
$9.55
52-Week Range:
$8.785
$13.53
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
9.185 | 2.85B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.63 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.49 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.75 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.35 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.69 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Y Intercept Hong Kong Ltd Purchases 85,951 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 - GlobeNewswire
HealthInvest Partners AB Has $3.08 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
State of New Jersey Common Pension Fund D Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Boosted by Transcend Capital Advisors LLC - MarketBeat
Wells Fargo & Company Lowers Amicus Therapeutics (NASDAQ:FOLD) Price Target to $17.00 - MarketBeat
Needham & Company LLC Reaffirms Hold Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat
Why Amicus Therapeutics, Inc. (FOLD) is the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey
Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to Hold at StockNews.com - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Amicus Therapeutics (FOLD) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Amicus Therapeutics files prospectus for stock sales By Investing.com - Investing.com Australia
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Call Transcript - MSN
Amicus Therapeutics CEO Campbell Bradley sells $4,000 in stock - Investing.com India
Amicus Therapeutics files prospectus for stock sales - Investing.com India
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Peregrine Capital Management LLC - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Stock Quotes, Forecast and News Summary - Benzinga
Form 424B5 AMICUS THERAPEUTICS, - StreetInsider.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lifted by Rice Hall James & Associates LLC - MarketBeat
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - Yahoo Finance
Amicus Therapeutics Navigates Potential Risks Amid U.S. Trade Policy Changes - TipRanks
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates - MSN
Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics - MSN
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down on Disappointing Earnings - MarketBeat
Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Amicus projects 17%-24% revenue growth in 2025, fueled by Fabry and Pompe therapies - MSN
Amicus Therapeutics Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Amicus Therapeutics: From Strong Growth to Exciting Future Projections - Jomfruland.net
Amicus Therapeutics Inc FOLD - Stockhouse Publishing
BofA cuts Amicus Therapeutics stock target to $14, keeps Buy rating - Investing.com Canada
AMICUS THERAPEUTICS, INC. SEC 10-K Report - TradingView
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm - Milton Daily Standard
AMICUS THERAPEUTICS Earnings Results: $FOLD Reports Quarterly Earnings - Nasdaq
Amicus Therapeutics Turns To Q4 Profit; Product Sales Grow 30% - Nasdaq
Amicus Therapeutics' Q4 Non-GAAP Earnings, Net Product Revenue Rise -February 19, 2025 at 07:34 am EST - Marketscreener.com
Amicus Therapeutics Reports Strong 2024 Financial Results and Positive Outlook for 2025 - TradingView
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates - GlobeNewswire
BRIEF-Amicus Therapeutics Q4 Net Income USD 14.7 Million - TradingView
Amicus Therapeutics Inc (FOLD) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Amicus Therapeutics stock hits 52-week low at $9.01 By Investing.com - Investing.com Nigeria
Amicus Therapeutics FY 2024 Earnings Preview - MSN
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.91%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):